These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 7981402)
21. A multiple-step selection procedure with sequential protection of preferred treatments. Chen TT; Simon R Biometrics; 1993 Sep; 49(3):753-61. PubMed ID: 8241371 [TBL] [Abstract][Full Text] [Related]
22. An adaptive weighted log-rank test with application to cancer prevention and screening trials. Self SG Biometrics; 1991 Sep; 47(3):975-86. PubMed ID: 1742450 [TBL] [Abstract][Full Text] [Related]
24. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data. Vickers AJ BMC Med Res Methodol; 2005 Nov; 5():35. PubMed ID: 16269081 [TBL] [Abstract][Full Text] [Related]
25. Predicting analysis times in randomized clinical trials. Bagiella E; Heitjan DF Stat Med; 2001 Jul; 20(14):2055-63. PubMed ID: 11439420 [TBL] [Abstract][Full Text] [Related]
26. On the design and analysis of randomized clinical trials with multiple endpoints. Tang DI; Geller NL; Pocock SJ Biometrics; 1993 Mar; 49(1):23-30. PubMed ID: 8513104 [TBL] [Abstract][Full Text] [Related]
27. Use of two-stage test statistic in the two-period crossover trials. Wang SJ; Hung HM Biometrics; 1997 Sep; 53(3):1081-91. PubMed ID: 9333341 [TBL] [Abstract][Full Text] [Related]
28. Interim analysis on survival data: its potential bias and how to repair it. van Houwelingen HC; van de Velde CJ; Stijnen T Stat Med; 2005 Sep; 24(18):2823-35. PubMed ID: 16025546 [TBL] [Abstract][Full Text] [Related]
32. Group sequential clinical trials for longitudinal data with analyses using summary statistics. Kittelson JM; Sharples K; Emerson SS Stat Med; 2005 Aug; 24(16):2457-75. PubMed ID: 15977295 [TBL] [Abstract][Full Text] [Related]
33. Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials. Wahed AS; Tsiatis AA Biometrics; 2004 Mar; 60(1):124-33. PubMed ID: 15032782 [TBL] [Abstract][Full Text] [Related]
34. [Methodological aspects of biostatistics and epidemiology in a clinical trial]. Suárez E; Pérez CM P R Health Sci J; 1999 Mar; 18(1):23-30. PubMed ID: 10343983 [TBL] [Abstract][Full Text] [Related]
35. Methods for mid-course corrections in clinical trials with survival outcomes. Cook TD Stat Med; 2003 Nov; 22(22):3431-47. PubMed ID: 14601011 [TBL] [Abstract][Full Text] [Related]
36. A comparison of two methods for adaptive interim analyses in clinical trials. Wassmer G Biometrics; 1998 Jun; 54(2):696-705. PubMed ID: 9629649 [TBL] [Abstract][Full Text] [Related]
37. Extension of the rank sum test for clustered data: two-group comparisons with group membership defined at the subunit level. Rosner B; Glynn RJ; Lee ML Biometrics; 2006 Dec; 62(4):1251-9. PubMed ID: 17156300 [TBL] [Abstract][Full Text] [Related]
38. Methods for the statistical analysis of binary data in split-cluster designs. Donner A; Klar N; Zou G Biometrics; 2004 Dec; 60(4):919-25. PubMed ID: 15606412 [TBL] [Abstract][Full Text] [Related]
40. Long-term survivor mixture model with random effects: application to a multi-centre clinical trial of carcinoma. Yau KK; Ng AS Stat Med; 2001 Jun; 20(11):1591-607. PubMed ID: 11391690 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]